The company said NUMETA G13E is indicated for PN administration for neonatal patients when oral or enteral nutrition is impossible, insufficient or contraindicated.
NUMETA addresses an important medical need to support neonatal patients who have acute nutritional requirements by providing a balanced formulation of amino acids (protein), glucose (carbohydrates), lipids (fats) and electrolytes in a triple-chamber system that was pioneered by the company.
According to the company, NUMETA G13E is designed for activation and administration at the point of care and ready-to-use PN may reduce the potential risk of medication errors and associated infections.
Baxters NUMETA G13E is a well-balanced, ready-to-use formula in a triple-chamber system that simplifies the preparation process for healthcare workers and helps reduce the potential risk to patients of infection and dosing errors, said Brik Eyre, president of Baxter's Hospital Products business.
Baxters NUMETA G13E has Marketing Authorization from the Competent Authorities in 15 Western European countries, including Austria, Belgium, France, Germany, Ireland, Malta Netherlands, Poland, Switzerland, the U.
Baxter offers additional pediatric triple-chamber PN solutions in Europe and select Latin American countries, including NUMETA G16E 500mL for term infants and toddlers (term infants through two years of age); and NUMETA G19E 1,000mL for children and adolescents (2-18 years of age).